Pyrimidine antitumor compound with Hedgehog antagonist activity

A hedgehog pathway and compound technology, applied in the field of pyrimidine anti-tumor compounds, can solve the problems of tumor metastasis and regeneration with little efficacy, and achieve the effect of blocking metastasis and regeneration and inhibiting abnormal cell growth.

Active Publication Date: 2014-02-19
SUZHOU KINTOR PHARMA
View PDF2 Cites 50 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Metastasis and regeneration are the characteristics of malignant tumors, and they are also difficult problems in the tr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine antitumor compound with Hedgehog antagonist activity
  • Pyrimidine antitumor compound with Hedgehog antagonist activity
  • Pyrimidine antitumor compound with Hedgehog antagonist activity

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0052] Example 1

[0053] This embodiment provides an anti-tumor compound A1, the synthesis method of the compound is as follows:

[0054]

[0055] 1) Synthesis of intermediate A1-2:

[0056] Dissolve 4-tert-butoxycarbonylpiperidone (A1-1, 10g, 50.2mmol) in 40 ml of N,N-dimethylformamide, add N,N-dimethylformamide dimethyl while stirring Acetal (6g, 50mmol), after the addition is complete, react at 80°C for 12 hours. Cooled to room temperature, added to ethyl acetate (150mL) and water (50mL), the organic phase was washed twice with saturated brine (50mL), dried over anhydrous sodium sulfate, filtered, and rotary evaporated to obtain an orange crude product (13g) directly Cast the next response.

[0057] 2) Synthesis of intermediate A1-3:

[0058] At room temperature, hemimethylthiourea sulfate (6.98g, 25.1mmol) and sodium ethoxide (3.28g, 40mmol) were dissolved in 40ml of ethanol, and after stirring for half an hour, the intermediate A1-2 synthesized in the previous step (13g, 50.2m...

Example Embodiment

[0070] Example 2

[0071] This embodiment provides an anti-tumor compound A2, and the synthesis method of the compound is as follows:

[0072]

[0073] 1) Synthesis of intermediate A2-1:

[0074] A1-4 (1g, 3.19mmol) and ethylamine aqueous solution (71%, 1mL, 15.8mmol) were dissolved in ethanol (10mL) with stirring, heated to reflux, after 12 hours, cooled to room temperature, and spin off under reduced pressure The solvent and concentrate are purified by column chromatography (mobile phase is petroleum ether: ethyl acetate=4:1) to obtain a white solid (400mg, 45%).

[0075] 2) Synthesis of intermediate A2-2:

[0076] Dissolve A2-1 (400mg, 1.44mmol) in a small amount of dichloromethane, add a saturated ethyl acetate solution (3mL) of hydrogen chloride, stir at room temperature for 3 hours, spin off the solvent under reduced pressure, and add the concentrate to a saturated aqueous sodium bicarbonate solution (5mL) and dichloromethane (20mL), the organic phase was washed with saturated b...

Example Embodiment

[0080] Example 3

[0081] This embodiment provides an anti-tumor compound A3. The synthesis method of the compound is as follows:

[0082]

[0083] 1) Synthesis of intermediate A3-1:

[0084] A1-4 (1g, 3.19mmol) and cyclopropylamine (300mg, 5.26mmol) were dissolved in ethanol (10mL) with stirring, heated to reflux, after 12 hours, cooled to room temperature, and the solvent was removed under reduced pressure. The concentrate Refined by column chromatography (mobile phase is petroleum ether:ethyl acetate=4:1) to obtain a white solid (460mg, 50%).

[0085] 2) Synthesis of intermediate A3-2:

[0086] Dissolve A3-1 (460mg, 1.58mmol) in a small amount of dichloromethane, add a saturated ethyl acetate solution (3mL) of hydrogen chloride, stir at room temperature for 3 hours, spin off the solvent under reduced pressure, and add the concentrate to a saturated aqueous sodium bicarbonate solution Wash (5mL) and dichloromethane (20mL), wash the organic phase with saturated brine (10mL), dry and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pyrimidine antitumor compound with Hedgehog antagonist activity, comprising the compound and pharmaceutically acceptable salts, various isotopes, various isomers or various crystal structures thereof. The pyrimidine antitumor compound has the structure shown as the general formula I, wherein, A refers to nitrogen atom or C-R9, n is 0, 1, 2, 3, 4, 5 or 6; the R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from hydrogen atom, alkyl, alkenyl, alkynyl, aromatic ring group, heterocyclic radical or heteroatom functional group-containing substituent group, respectively. The antitumor compound provided by the invention can block Hedgehog through blocking an SMO (Smoothened receptor) so as to inhibit cell abnormal growth and block tumor cell migration generation, and has an obvious antitumor effect.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular to a pyrimidine antitumor compound with hedgehog pathway antagonist activity. Background technique [0002] Malignant tumors are one of the most important diseases that endanger human health. There are about 10.9 million new cases of malignant tumors in the world every year, and about 6.7 million patients die of malignant tumors every year [1]. The research and development of anti-tumor drugs has undergone tremendous changes after years of research and exploration; the anti-tumor drugs commonly used in clinical treatment in the past are mainly cytotoxic drugs, which have poor selectivity, strong toxic and side effects, and are easy to treat. In recent years, with the rapid development of life science research, the signal transduction in malignant tumor cells, the regulation of cell cycle, the induction of apoptosis, angiogenesis and the interaction between cells and extrace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D471/04C07D487/04A61K31/519A61K31/53A61K31/4985A61K31/4375A61K31/55A61K31/5025A61P35/00A61P35/02
CPCC07D471/04C07D487/04
Inventor 张小虎
Owner SUZHOU KINTOR PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap